Release Date: 2024-06-10
F-18 FDG PET/CT- 2: Common Oncological Applications
Fatih Guzel (Author)
Release Date: 2024-06-10
The aims for which PET/CT is frequently used in oncology can be listed as follows. Benign/malignant distinction of lesions Primary focus investigation in patients with metastasis or paraneoplastic syndrome Staging and evaluation of treatment response in c During post-treatment follow-ups, discrimination of lesions observed in other imaging modalities in terms of [...]
Media Type
Buy from
Price may vary by retailers
| Work Type | Book Chapter |
|---|---|
| Published in | The Radiology of Cancer |
| First Page | 461 |
| Last Page | 468 |
| DOI | https://doi.org/10.69860/nobel.9786053359364.29 |
| Page Count | 8 |
| Copyright Holder | Nobel Tıp Kitabevleri |
| License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Benign/malignant distinction of lesions
Primary focus investigation in patients with metastasis or paraneoplastic syndrome
Staging and evaluation of treatment response in c
During post-treatment follow-ups, discrimination of lesions observed in other imaging modalities in terms of residual tumor or fibrosis
Investigation of recurrence in patients with elevated tumor markers
Determining the area to be biopsied in tumors
Guidance on radiotherapy (RT) planning
It is known that PET provides significant benefits in oncological patient management, especially with treatment response evaluation. Indications for the use of F-18 FDG PET / CT (Positron emission tomography / Computed Tomography) in oncology are increasing day by day. In this section, the most common oncological F-18 FDG PET applications in nuclear medicine clinics will be discussed.
Fatih Guzel (Author)
Dicle University
https://orcid.org/0000-0002-8571-3418
3Dr. Fatih Güzel graduated from Dicle University Faculty of Medicine in 2018. He then worked at Silvan District Health Directorate. In 2020, he started working as a research assistant in Dicle University Medical Faculty, Department of Nuclear Medicine. Dr. Güzel has been involved in many research projects. He also actively participated in many national congresses. Dr. Güzel has been working as a specialist physician at Gazi Yaşargil Education Research Hospital since 2024 and continues to contribute to academic studies.
Sheikhbahaei, S., Verde, F., Hales, R. K., Rowe, S. P., & Solnes, L. B. (2020). Imaging in therapy response assessment and surveillance of lung cancer: evidenced-based review with focus on the utility of 18F-FDG PET/CT. Clinical lung cancer, 21(6), 485-497.
Turgeon, G. A., Iravani, A., Akhurst, T., Beaulieu, A., Callahan, J. W., Bressel, M., et al. (2019). What 18F-FDG PET response-assessment method best predicts survival after curative-intent chemoradiation in non–small cell lung cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?. Journal of Nuclear Medicine, 60(3), 328-334.
Kulkarni, N. M., Pinho, D. F., Narayanan, S., Kambadakone, A. R., Abramson, J. S., & Sahani, D. V. (2017). Imaging for oncologic response assessment in lymphoma. American Journal of Roentgenology, 208(1), 18-31.
Meignan, M. (2015). VI. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis. Hematological Oncology, 33, 38-41.
Moghbel, M. C., Mittra, E., Gallamini, A., Niederkohr, R., Chen, D. L. et al. (2017). Response assessment criteria and their applications in lymphoma: part 2. Journal of Nuclear Medicine, 58(1), 13-22.
Freudenberg, L. S., Antoch, G., Schütt, P., Beyer, T., Jentzen, W., Müller et al (2004). FDG-PET/CT in restaging of patients with lymphoma. European journal of nuclear medicine and molecular imaging, 31, 325-329.
Mikhaeel, N. G., Timothy, A. R., O’doherty, M. J., Hain, S., & Maisey, M. N. (2000). 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT. Leukemia & lymphoma, 39(5-6), 543-553.
Mütevelizade, G. Y. (2021). PET/CT in the Evaluation of the Treatment Response in Lymphomas. Nukleer Tıp Seminerleri, 7(2), 177.
Barrington, S. F., Qian, W., Somer, E. J., Franceschetto, A., Bagni, B., et al. (2010). Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European journal of nuclear medicine and molecular imaging, 37, 1824-1833.
World Health Organization. World cancer report. Geneva, Switzerland: World Health Organization, 2014
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R. et al. (2021). NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 19(3), 254-266.
Choi, S. H., Kim, Y. T., Kim, S. K., Kang, K. W., Goo, J. M., Kang, C. H., & Kim, J. H. (2011). Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. The Annals of thoracic surgery, 92(5), 1826-1832.
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a cancer journal for clinicians, 68(1), 7-30.
Fowler, A. M., Mankoff, D. A., & Joe, B. N. (2017). Imaging neoadjuvant therapy response in breast cancer. Radiology, 285(2), 358-375.
Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016). Incidence and mortality and epidemiology of breast cancer in the world. Asian Pacific journal of cancer prevention, 17(sup3), 43-46.
Paydary, K., Seraj, S. M., Zadeh, M. Z., Emamzadehfard, S., Shamchi, S. P., Gholami, S., Alavi, A. (2019). The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer. Molecular imaging and biology, 21, 1-10.
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H.,... & Kumar, R. (2022). Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 20(6), 691-722.
Ulaner, G. A. (2019). PET/CT for patients with breast cancer: where is the clinical impact?. American Journal of Roentgenology, 213(2), 254-265.
Groheux, D. (2018). Role of fludeoxyglucose in breast cancer: treatment response. PET clinics, 13(3), 395414.
Liu, Q., Wang, C., Li, P., Liu, J., et al. (2016). The role of 18 F-FDG PET/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis. BioMed research international, 2016.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., et al.(2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
Aykan, N., YALÇIN, Ş., Turhal, N., Ozdogan, M., Demir, G., et al. (2015). Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial). Turkish Journal of Gastroenterology, 26(2).
Kekelidze, M., D’Errico, L., Pansini, M., et al. (2013). Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World journal of gastroenterology: WJG, 19(46), 8502.
McKeown, E., Nelson, D. W., Johnson, E. K., Maykel, J. A., Stojadinovic, A., et al. (2014). Current approaches and challenges for monitoring treatment response in colon and rectal cancer. Journal of Cancer, 5(1), 31.
Young, P. E., Womeldorph, C. M., Johnson, E. K., Maykel, J. A., et al.(2014). Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. Journal of Cancer, 5(4), 262.
| onix_3.0::thoth | Thoth ONIX 3.0 |
|---|---|
| onix_3.0::project_muse | Project MUSE ONIX 3.0 |
| onix_3.0::oapen | OAPEN ONIX 3.0 |
| onix_3.0::jstor | JSTOR ONIX 3.0 |
| onix_3.0::google_books | Google Books ONIX 3.0 |
| onix_3.0::overdrive | OverDrive ONIX 3.0 |
| onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
| csv::thoth | Thoth CSV |
| json::thoth | Thoth JSON |
| kbart::oclc | OCLC KBART |
| bibtex::thoth | Thoth BibTeX |
| doideposit::crossref | CrossRef DOI deposit |
| onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
| marc21record::thoth | Thoth MARC 21 Record |
| marc21markup::thoth | Thoth MARC 21 Markup |
| marc21xml::thoth | Thoth MARC 21 XML |
